Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals director Anne O'Riordan will not stand for re-election in 2026

Neutral Impact 2 of 5 leadership Written later

Jazz Pharmaceuticals said Class III director Anne O'Riordan told the board on May 25, 2026 that she will not stand for re-election at the 2026 annual meeting of shareholders. The company said her decision was not the result of any dispute or disagreement with the company or the board on its operations, policies or practices, and that the board will continue to evaluate its composition and manage orderly succession.

Key points

  • Anne O'Riordan, a Class III director, informed the board on May 25, 2026 that she will not stand for re-election.
  • Her term expires at the 2026 annual meeting of shareholders.
  • The company said the departure was not due to any dispute or disagreement with the company or board.
  • The filing was signed by Neena Patil, Executive Vice President and Chief Legal Officer, on May 29, 2026.

The filing

CompanyJazz Pharmaceuticals (JAZZ)
Form8-K, current report
Filed with the SECMay 29, 2026, 4:05 PM ET
Accession number0001628280-26-039147

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:11 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 29, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.